NCT06247787 2026-04-20A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology GroupPhase 1 Recruiting36 enrolled
NCT02598661 2026-01-05Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/3 Active not recruiting289 enrolled 35 charts 2 FDA
NCT04576156 2025-12-04A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentGeron CorporationPhase 3 Active not recruiting327 enrolled